Medarex, BMY melanoma deal

MEDX and Bristol-Myers (BMY) partnered to develop MEDX's MDX-010 anti- CTLA-4 antibody and MDX-1379 gp100 peptide vaccine to

Read the full 184 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE